BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.

Daniele MartinelliSebastiano ArceriRoberto De IccoMarta AllenaElena GuaschinoNatascia GhiottoVito BitettoGloria CastellazziGiuseppe CosentinoGrazia SancesCristina Tassorelli

Published in: Cephalalgia : an international journal of headache (2021)

The findings suggest that, when administered according to the PREEMPT paradigm, onabotulinum toxin-A is effective in the prevention of high-frequency episodic migraine.Trial Registration: NCT04578782.

Keyphrases

high frequency
transcranial magnetic stimulation
escherichia coli
clinical trial
phase ii